Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current opinion in pulmonary medicine

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MCP.0b013e32835d8ea4PMID 23287286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Progression of Chronic Obstructive Pulmonary Disease on the Energy Metabolism

  2015cited by this paper
• Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial

  2011cited by this paper
• Changes in forced expiratory volume in 1 second over time in COPD.

  2011cited by this paper
• The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.

  2011cited by this paper
• Chronic obstructive pulmonary disease phenotypes: the future of COPD.

  2010cited by this paper
• COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

  2010cited by this paper
• Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial

  2010cited by this paper
• Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

  2009cited by this paper
• Genetics and genomics of chronic obstructive pulmonary disease.

  2009cited by this paper
• The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort.

  2009cited by this paper
• Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial

  2009cited by this paper
• The many "small COPDs": COPD should be an orphan disease.

  2008cited by this paper
• A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

  2008cited by this paper
• Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

  2008cited by this paper
• Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease.

  2007cited by this paper
• A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

  2007cited by this paper
• Longitudinal Limits of Normal Decline in Lung Function in an Individual

  2006cited by this paper
• Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.

  2005cited by this paper
• Determinants of maximally attained level of pulmonary function.

  2004cited by this paper
• Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis.

  2003cited by this paper
• American Thoracic Society Statement: Occupational contribution to the burden of airway disease.

  2003cited by this paper
• Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

  2003cited by this paper
• Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

  2001cited by this paper
• Susceptibility genes for rapid decline of lung function in the lung health study.

  2001cited by this paper
• Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

  2000cited by this paper
• LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING

  2000cited by this paper
• Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

  2000cited by this paper
• Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

  2000cited by this paper
• Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.

  1999cited by this paper
• Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

  1999cited by this paper
• Decline of FEV1 by age and smoking status: facts, figures, and fallacies.

  1997cited by this paper
• Overview of issues in the longitudinal analysis of respiratory data.

  1996cited by this paper
• Occupational and chronic obstructive pulmonary disease (COPD)

  1996cited by this paper
• Longitudinal analyses of airway responsiveness and pulmonary function decline.

  1996cited by this paper
• The relationship of childhood respiratory infection to growth and decline in lung function.

  1996cited by this paper
• Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

  1996cited by this paper
• Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

  1995cited by this paper
• Occupation and chronic obstructive pulmonary disease.

  1994cited by this paper
• Gender difference in smoking effects on adult pulmonary function.

  1994cited by this paper
• Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences.

  1994cited by this paper
• The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second.

  1994cited by this paper
• Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1

  1994cited by this paper
• The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group.

  1992cited by this paper
• Longitudinal lung function decline in subjects with respiratory symptoms.

  1992cited by this paper
• The Lung Health Study: Airway Responsiveness to Inhaled Methacholine in Smokers with Mild to Moderate Airflow Limitation

  1992cited by this paper
• Pulmonary status of habitual cocaine smokers.

  1992cited by this paper
• The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease.

  1989cited by this paper
• Effects of smoking and changes in smoking habits on the decline of FEV1.

  1989cited by this paper
• The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms.

  1988cited by this paper
• Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation.

  1987cited by this paper
• Decreases in VC and FEV1 with time: indicators for effects of smoking and air pollution.

  1981cited by this paper
• The natural history of chronic airflow obstruction.

  1977cited by this paper

• Investigating Temporal PM2.5 Exposure in Relation to Rapid Lung-Function Decline Among COPD Patients: a Retrospective Study

  2025cites this paper
• Medication use of Canadians with chronic obstructive pulmonary disease: a cohort study

  2023cites this paper
• Effects of Nutritional Interventions in Individuals with Chronic Obstructive Lung Disease: A Systematic Review of Randomized Controlled Trials

  2021cites this paper
• Bronchial gene expression signature associated with rate of subsequent FEV1 decline in individuals with and at risk of COPD

  2021cites this paper
• Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers

  2021cites this paper
• Asthma-Chronic Obstructive Pulmonary Disease Overlap.

  2020cites this paper
• Acute exacerbation of chronic obstructive pulmonary disease in older people

  2019cites this paper
• Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting

  2019cites this paper
• Effects of Alcohol on Pulmonary Function in a Healthy Population

  2019cites this paper
• COPD_A_200919 1063..1073

  2019cites this paper
• Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review

  2019cites this paper
• Environmental exposures and systemic hypertension are risk factors for decline in lung function

  2018cites this paper
• COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2017cites this paper
• Pulmonary Diseases, a Matter of Time

  2017cites this paper
• Phenotyping Before Starting Treatment in COPD?

  2017cites this paper
• GOLD Classification of COPD: Discordance in Criteria for Symptoms and Exacerbation Risk Assessment

  2017cites this paper
• Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.

  2016cites this paper
• COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2016cites this paper
• Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands

  2016cites this paper
• Prioritization of COPD protein biomarkers, based on a systematic study of the literature

  2016cites this paper
• Aging in COPD and Idiopathic Pulmonary Fibrosis

  2016cites this paper
• Individual FEV1 Trajectories Can Be Identified from a COPD Cohort

  2016cites this paper
• Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation Free Urinary Desmosine and Isodesmosine as COPD Biomarkers : The Relevance of Confounding Factors

  2016cites this paper
• Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

  2015cites this paper
• Individual Trajectories in Asthma and COPD: A Longitudinal Perspective to Obstructive Lung Disease

  2015cites this paper
• The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods

  2015cites this paper
• The Asthma-COPD Overlap Syndrome.

  2015cites this paper
• Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial

  2015cites this paper
• Developmental genetics of the COPD lung

  2015cites this paper
• Increased Decline in Pulmonary Function Among Employees in Norwegian Smelters Reporting Work-Related Asthma-Like Symptoms

  2015cites this paper
• Efficacy of a multifactorial intervention on therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled trial

  2014cites this paper
• Long-acting bronchodilators in COPD: where are we now and where are we going?

  2014cites this paper
• The diagnosis of chronic obstructive pulmonary disease.

  2014cites this paper
• FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure.

  2014cites this paper
• Acute exacerbations of chronic obstructive pulmonary disease: causes and impacts.

  2014cites this paper
• Respiratory failure in COPD

  2013cites this paper
• Early chronic obstructive pulmonary disease: Beyond spirometry

  2013cites this paper
• Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD.

  2013cites this paper